SCHEMBL2902265

SCHEMBL2902265

Cc1ccc(CNc2ccc3c(Nc4cc(F)cc(F)c4)cccc3n2)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.37
NPY5R Q15761 1/20 0.37
MAPK14 Q16539 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.35
TRPC5 Q9UL62 1/20 0.35
EGFR P00533 2/20 0.35
KDR P35968 2/20 0.35
MAPK1 P28482 1/20 0.35
NTRK1 P04629 1/20 0.35
HRH4 Q9H3N8 1/20 0.34
KDM4E B2RXH2 3/20 0.34
SLC2A1 P11166 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901522 0.91 RAB9A (0.41) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2908410 0.88 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2907784 0.88 NTRK1 (0.41) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2908916 0.85 TGFBR1 (0.42) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2902008 0.84 LMNA (0.45) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2901736 0.83 L3MBTL1 (0.40) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2902332 0.82 RAB9A (0.39) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2906805 0.82 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HTTLMNA
SCHEMBL2901754 0.82 MEN1 (0.43) NPC1RAB9ASMN1; SMN2LMNATSHR
SCHEMBL2907376 0.81 EPHB4 (0.43) NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US claimed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US claimed
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 NPC1 1573/4885RAB9A 1336/4885SMN1; SMN2 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.